Table 2.
Initial randomization | 3-year survival | Median OS |
---|---|---|
Vaccine (V) | 81% | 5.1 yrs |
Nilutamide | 62% | 3.4 yrs |
Crossover at progression | ||
V then V + N | 100% | 6.2 yrs |
N then N + V | 75% | 3.7 yrs |
Initial randomization | 3-year survival | Median OS |
---|---|---|
Vaccine (V) | 81% | 5.1 yrs |
Nilutamide | 62% | 3.4 yrs |
Crossover at progression | ||
V then V + N | 100% | 6.2 yrs |
N then N + V | 75% | 3.7 yrs |